Literature DB >> 11726088

Visual event-related potentials in cirrhotic patients without overt encephalopathy: the effects of flumazenil.

E A Jones1, V I Giger-Mateeva, D Reits, F C Riemslag, B Liberov, H Spekrijse.   

Abstract

The P300 complex was derived from the electroencephalogram (EEG) as subjects mentally counted infrequent large checkerboard visual stimuli, presented randomly among frequent small checkerboard stimuli. Use of low contrast (10%) stimuli and four midline scalp electrodes, facilitated separation of cognitive and sensory components and enabled the P300 complex to be resolved into three distinct components--N200, P3a, and P3b. In 20 healthy adult subjects normative data were established and the P3a and P3b components were shown to depend on cognitive function. In 19 age-matched cirrhotic patients without overt hepatic encephalopathy (HE) the EEG and visual evoked potentials (VEPs) were normal, but latencies of P3a and/or P3b were prolonged in 9. Prolonged latencies were not associated with an abnormal number connection test. Ten additional age-matched cirrhotic patients without overt HE, who were alcohol, drug, and caffeine free, were randomized to receive flumazenil (1 mg) and placebo intravenously, double-blind. After flumazenil or placebo, latencies of P3a and P3b and psychometric test results did not change significantly. These findings suggest that in cirrhotic patients without overt HE (i) impaired cognitive sensory function may occur in the absence of abnormalities of a standard psychometric test, the EEG, or VEPs, and (ii) increased latencies of P3a and P3b may constitute a component of subclinical HE, which is not mediated by increased brain levels of central benzodiazepine receptor agonist ligands.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11726088     DOI: 10.1023/a:1011662411913

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  19 in total

Review 1.  Does ammonia contribute to increased GABA-ergic neurotransmission in liver failure?

Authors:  E A Jones; A S Basile
Journal:  Metab Brain Dis       Date:  1998-12       Impact factor: 3.584

2.  Interindividual variability of the number connection test.

Authors:  M L Zeneroli; G Cioni; P Ventura; A M Russo; I Venturini; G Casalgrandi; E Ventura
Journal:  J Hepatol       Date:  1992-05       Impact factor: 25.083

Review 3.  Flumazenil: potential implications for hepatic encephalopathy.

Authors:  E A Jones; A S Basile; K D Mullen; S H Gammal
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

Review 4.  Newer approaches to therapy of hepatic encephalopathy.

Authors:  P Ferenci; A Herneth; P Steindl
Journal:  Semin Liver Dis       Date:  1996-08       Impact factor: 6.115

5.  Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy.

Authors:  H O Conn
Journal:  Am J Dig Dis       Date:  1977-06

6.  The pattern flash elicited P300-complex (PF-P300): a new method for studying cognitive processes of the brain.

Authors:  A Taghavy; C F Kügler
Journal:  Int J Neurosci       Date:  1988-01       Impact factor: 2.292

7.  The effect of flumazenil on visual event-related potentials of clinically non-encephalopathic patients with cirrhosis.

Authors:  V I Giger-Mateeva; D Reits; B Liberov; E A Jones; H Spekreijse
Journal:  Neurosci Lett       Date:  1999-12-10       Impact factor: 3.046

8.  The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy, ambulant, non-shunted patients with cirrhosis.

Authors:  N Gitlin; D C Lewis; L Hinkley
Journal:  J Hepatol       Date:  1986       Impact factor: 25.083

9.  Successful long-term treatment of portal-systemic encephalopathy by the benzodiazepine antagonist flumazenil.

Authors:  P Ferenci; G Grimm; S Meryn; A Gangl
Journal:  Gastroenterology       Date:  1989-01       Impact factor: 22.682

10.  Objective measurement of hepatic encephalopathy by means of automated EEG analysis.

Authors:  C C Van der Rijt; S W Schalm; G H De Groot; M De Vlieger
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1984-05
View more
  5 in total

Review 1.  Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

Authors:  Ee Teng Goh; Mette L Andersen; Marsha Y Morgan; Lise Lotte Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-07-26

Review 2.  Flumazenil versus placebo or no intervention for people with cirrhosis and hepatic encephalopathy.

Authors:  Ee Teng Goh; Mette L Andersen; Marsha Y Morgan; Lise Lotte Gluud
Journal:  Cochrane Database Syst Rev       Date:  2017-08-10

Review 3.  Methods for diagnosing hepatic encephalopathy in patients with cirrhosis: a multidimensional approach.

Authors:  Sara Montagnese; Piero Amodio; Marsha Y Morgan
Journal:  Metab Brain Dis       Date:  2004-12       Impact factor: 3.584

4.  Event-related evoked potential versus clinical tests in assessment of subclinical cognitive impairment in chronic hepatitis C virus.

Authors:  Hanaa Khalaf Fath-Elbab; Elham Ahmed; Dina Fathy Mansour; Wail Talaat Soliman
Journal:  Egypt J Neurol Psychiatr Neurosurg       Date:  2018-11-20

5.  Performance of a self-paced brain computer interface on data contaminated with eye-movement artifacts and on data recorded in a subsequent session.

Authors:  Mehrdad Fatourechi; Rabab K Ward; Gary E Birch
Journal:  Comput Intell Neurosci       Date:  2008
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.